



16 December 2022

**Christmas wish granted!  
Trikafta RECOMMENDED for 6 – 11-years.**

We have been on the edge of our seats waiting to hear the outcome of the November PBAC meeting and whether Trikafta would be recommended for the 6–11-year-old age group.

I am delighted that this positive recommendation has been made for 6–11-year-olds who have at least one F508del mutation on the CFTR gene.

This is the right decision, and Aussie kids will have a lifetime of benefits as a result.

Thank you to every one of you who made a submission to the PBAC, including the CF federation members. Together we are supporting Aussies with CF to have abundant lives.

We would like to sincerely thank Vertex and the PBAC for coming to this decision and particularly, the Chair, Andrew Wilson and Deputy Chair, Jo Watson, for their involvement in this process.

Special thanks to the Department of Health and the Minister for Health, Hon Mark Butler, MP, and his Senior Advisor, for their role supporting Australians with cystic fibrosis in 2022. The support of our nation's leaders is critical to ensure that Australian's living with cystic fibrosis can live longer, healthier lives.

We have seen the great benefits of Trikafta for the 12+ age group for those with at least one F508 del mutation and hopefully soon 500+ children will be able to benefit too.

While the recommendation is brilliant news, our 6–11-year old's need access to [#TrikaftaNOW](#)

We urge the government and Vertex to ensure that Trikafta is made available without delay, so that our children can benefit immediately. The sooner Trikafta is available, the sooner the benefits can be realised, including reduction in infection, reduced hospitalisation, and the opportunity for a better quality of life.

We have our Christmas wish granted and now we need our children to be able to access [#TrikaftaNOW](#)

While not everyone will benefit directly from this outcome, it is certainly progress for our community as more people are gaining access to the life changing treatments they require.

Cystic Fibrosis Australia remains committed to securing the best health outcomes for everyone in the community and will continue working to ensure that no one is left behind, especially those who are not eligible for modulator therapies or do not respond to them. You are not forgotten. We will continue to strive for outcomes that benefit everyone.



Merry Christmas and thank you for your support.

Jo Armstrong  
**Chief Executive Officer**  
**Cystic Fibrosis Australia**